Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: diablo who wrote (347)	7/14/1998 7:44:00 AM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 1494

Yes I am in NTII heavily and holding. I have no inside information. I understand that Freiman is on the road meeting with large pharmaceutical companies looking for a partner for memantine. I might be surprised, but, I don't expect significant news until the Fall. The first we should hear about is some form of financing for the company, probably a private placement. The real fireworks should come in the Winter, when I expect a partnership to be announced, application for the NASDAQ small cap market filed, and the results from the AIDS dementia trial for memantine and the peritumoral edema trial for Xerecept to be announced. In the meantime, I'm accumulating. At a buck a share, with the Merz partnership taking most of the risk out of NTII, IMHO it's a steal. It will take a little patients, six to nine months. But, the payoff should be substantial. Best regards John de C